172 recruiting. 172 Phase 1, 75 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 172 | Recruiting 172 |
| Phase 2 | 75 | Recruiting 75 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine - Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | Phase 1 | Recruiting | Weill Medical College of Cornell University | 32 | 2026-11-01 | 2026-10-26 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-28 | 2026-11-02 |
| A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma IBI3003 - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fortvita Biologics (USA)Inc. | 360 | 2026-09-30 | 2026-09-25 |
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 38 | 2026-09-30 | 2026-10-05 |
| Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers 6MW5311 - AML, Multiple Myeloma | Phase 1 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 122 | 2026-09-16 | 2026-11-03 |
| A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma CT0596 - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | UCARsgen Biotech Limited | 68 | 2026-09-03 | 2026-09-17 |
| Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA KSVCBD injection - Multiple Myeloma | Phase 1 | Recruiting | Chinese PLA General Hospital | 9 | 2026-09-03 | 2026-09-15 |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose) - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2026-08-05 | 2026-11-04 |
| In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma Invivo CAR-T - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 15 | 2026-07-31 | 2026-07-20 |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-11-02 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-10-29 |
| A Clinical Study of SHR-5421 in Patients With Multiple Myeloma SHR-5421 for Injection - Multiple Myeloma | Phase 1 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 97 | 2026-07-23 | 2026-07-30 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders GPRC5D-Targeted PET/CT Imaging - Plasma Cell Disorders, Multiple Myeloma (MM) | Phase 1 | Recruiting | Peking University First Hospital | 50 | 2026-06-25 | 2026-09-28 |
| A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) RO7851624 - Relapsed/Refractory Multiple Myeloma | Phase 1 | Recruiting | Genentech, Inc. | 160 | 2026-06-23 | 2026-10-09 |
| A Study of ARC-02 in B-cell NHL ARC-02, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Taiho Oncology, Inc. | 140 | 2026-06-22 | 2026-11-02 |
| Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) NT-I7, Placebo - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Washington University School of Medicine | 52 | 2026-06-05 | 2026-10-15 |
| DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia DIAG723, Placebo - Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | Recruiting | Diagonal Therapeutics, Inc. | 93 | 2026-06-04 | 2026-09-08 |
Showing 20 of 172. Sign in to see all of them.
Multiple Myeloma (148) · Recurrence (30) · Waldenstrom Macroglobulinemia (19) · Lymphoma, Follicular (18) · Lymphoma, B-Cell, Marginal Zone (17) · Lymphoma, Mantle-Cell (16) · Lymphoma, Large B-Cell, Diffuse (14) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Neoplasms, Plasma Cell (12) · Lymphoma, Non-Hodgkin (11) · Neoplasms (11) · Hematologic Neoplasms (9) · Leukemia, Myeloid, Acute (9) · Lymphoma, B-Cell (9)
Hemic and Lymphatic Diseases (172) · Cardiovascular Diseases (169) · Hemorrhagic Disorders (169) · Vascular Diseases (168) · Hematologic Diseases (167) · Immune System Diseases (164) · Immunoproliferative Disorders (164) · Lymphoproliferative Disorders (164) · Neoplasms by Histologic Type (164) · Blood Protein Disorders (163) · Paraproteinemias (163) · Neoplasms (156) · Neoplasms, Plasma Cell (155) · Pathologic Processes (45)
Dexamethasone (28) · daratumumab (15) · Lenalidomide (12) · pomalidomide (12) · Calcium Dobesilate (10) · Cyclophosphamide (10) · carfilzomib (10) · Magnetic Resonance Spectroscopy (9) · Biopsy (8) · iberdomide (8) · Specimen Handling (7) · fludarabine (5) · Bortezomib (4) · Injections (4) · belantamab mafodotin (4)
Regeneron Pharmaceuticals (6) · AbbVie (5) · AstraZeneca (4) · Chongqing Precision Biotech Co., Ltd (4) · Mayo Clinic (4) · Washington University School of Medicine (4) · BeOne Medicines (3) · Genentech, Inc. (3) · Medical College of Wisconsin (3) · National Cancer Institute (NCI) (3) · Xuzhou Medical University (3) · Beijing GoBroad Hospital (2) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2) · City of Hope Medical Center (2) · David Avigan (2)
United States (99) · China (60) · Australia (25) · Spain (25) · France (21) · United Kingdom (21) · Canada (15) · Germany (13) · Israel (12) · Japan (12) · South Korea (11) · Italy (10) · Poland (10) · Greece (7) · Norway (6)
Binod Dhakal, MD (2) · Cheng Qian, PhD (2) · Murali Janakiram (2) · Sanbin Wang, MD (2) · Alfred Chung, MD (1) · Anders Holmberg (1) · Andrew Hantel, MD (1) · Andrew J. Yee, MD (1) · Armin Ghobadi, M.D. (1)
PMID 36375120, PMID 41100731, PMID 41118600, PMID 25319501, PMID 27412889, PMID 30352784, PMID 30595484, PMID 31937615, PMID 32758410, PMID 33717057, PMID 34464155, PMID 34903705, PMID 35175355, PMID 35432352, PMID 35488407, PMID 35798714, PMID 35946431, PMID 36059523, PMID 36477110, PMID 36482815, PMID 36690556, PMID 36898933, PMID 37393120, PMID 37774014, PMID 37883795, PMID 38643346, PMID 38698840, PMID 38826786, PMID 38879802, PMID 39261676, PMID 41144785, PMID 41387038, PMID 41708325, PMID 41719502, PMID 41980020, PMID 42206665, PMID 42564571, PMID 42786443
2023 (12), 2025 (4), P30CA033572 (2), P30CA138292 (1), P50CA186781 (1), R01CA262613 (1), R01CA271606 (1), U10CA180820 (1), UM1CA186709 (1)